Dermatology specialist Galderma (SWX:GALD) on Thursday announced the publication of positive Phase III OLYMPIA 1 trial results for nemolizumab in JAMA Dermatology.
The drug demonstrated significant improvements in itch and skin lesions in patients with moderate-to-severe prurigo nodularis.
Nemolizumab, a first-in-class monoclonal antibody targeting IL-31, showed rapid and sustained relief from itch and sleep disturbance. The drug has already been approved by the US Food and Drug Administration (FDA) for the treatment of prurigo nodularis in adults and is currently under review by regulatory authorities worldwide for both prurigo nodularis and atopic dermatitis.
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
TuHURA Biosciences acquires Kineta
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer